Navigation Links
MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
Date:3/19/2009

WOONSOCKET, R.I., March 19 /PRNewswire-FirstCall/ --MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today that it has entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of liver stem cells and liver cancer.

Tumor tissues are composed of a mixture of cells with some tumor cells exhibiting stem cell-like properties (cancer stem cells). Cancer stem cells are thought to play a role in a tumor's resistance to therapy. While significant progress has been made in developing cancer therapies that result in cytoreduction and thus tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. Cancer stem cells are believed to be responsible for cancer relapse by being less sensitive to conventional therapies. Cancer stem cells may offer a unique opportunity to identify and develop a new generation of more effective anticancer agents (both small molecule therapeutics and biotherapies).

MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of liver stem cells. The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells.

Primary liver cancer begins in the cells of the liver itself. According to the National Cancer Institute (NCI), in 2008 there were approximately 21,400 new cases of primary liver cancer and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, wit
'/>"/>

SOURCE MultiCell Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
2. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
3. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
4. Neuro Kinetics: Research Suggests I-Portal(R) NOTC Data Shows Mild Traumatic Brain Injuries That Other Technologies Miss
5. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
6. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
7. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
8. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
9. ImmunoVaccine Technologies DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
10. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
11. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Technologies, Inc., developers of the AcceleDent System ... orthodontics, announced the availability of a new Continuing ... a leader in professional education for many industries, ... on patient views about orthodontic treatment, a summary ...
(Date:12/4/2009)... TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced ... Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected ... across the country. The grand prize is an in-person meeting ... type 1 diabetes like Nick, are: Caleb, age 6, from ...
(Date:12/4/2009)... ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) announced ... allowed its patent application on a system for automation ... Company,s DCVax® therapeutic cancer vaccines. These initial manufacturing ... dendritic cells (which are the critical ingredient) in the ...
Breaking Medicine Technology:AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5National Poll Finds Most Americans Believe Immigration Adversely Affects the Quality and Cost of Healthcare 57264 1National Poll Finds Most Americans Believe Immigration Adversely Affects the Quality and Cost of Healthcare 57264 2Cowen Announces Hiring of Don Munoz to Lead Medical Technology Practice 3B 5th Senior Level Addition to Cowens Health Care Franchise in 2009 57260 1Cowen Announces Hiring of Don Munoz to Lead Medical Technology Practice 3B 5th Senior Level Addition to Cowens Health Care Franchise in 2009 57260 2Indiana U medical researchers boost research and jobs with stimulus legislation grants 57257 1Indiana U medical researchers boost research and jobs with stimulus legislation grants 57257 2Indiana U medical researchers boost research and jobs with stimulus legislation grants 57257 3Indiana U medical researchers boost research and jobs with stimulus legislation grants 57257 4
... MACE, Zero Late Stent Thrombosis,- Company Also Provides Clinical Program Update ... ... -, WASHINGTON, Oct. 22 XTENT, Inc. (Nasdaq:,XTNT) today announced ... prospective studies evaluating the safety and,efficacy of its Custom NX(R) drug-eluting ...
... 21 Sanofi-aventis announced today,that the Japanese ... has granted,approval for a Supplemental New Drug ... syndrome (unstable angina pectoris, non-ST elevation,myocardial infarction) ... planned" for Plavix(R) (clopidogrel). Approximately 100,000 ...
Other Medicine Technology:XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System 2XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System 3XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System 4Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 2Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 4Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 5
(Date:12/6/2009)... 6 Onyx Pharmaceuticals, Inc. (Nasdaq: ... the pivotal Phase 2b 003-A1 study, known as ... in heavily pre-treated relapsed and refractory multiple myeloma ... ASH/ASCO Joint Symposium at the 51st annual meeting ... New Orleans. Enrollment in this trial is complete ...
(Date:12/6/2009)... site www.sleeping-with-a-sleeping-disorder.com is asking people ,who ... sleep aids from around the world to donate ... The submissions will be compiled in an ebook ... to be sold from the website in early ... the proceeds ,from sales of the E-book to ...
(Date:12/5/2009)... Dec. 5 There have been significant scientific advances ... continue to gain a better understanding of how certain ... and provide patients with the best care. Research presented ... Society of Hematology explores optimal induction therapies for managing ...
(Date:12/5/2009)... ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders ... presented today at the 51st Annual Meeting of ... treatment options and improved diagnostic methods for patients ... infant acute lymphoblastic leukemia, and myelofibrosis that are ...
(Date:12/5/2009)... today announced the launch of International Solutions, an innovative new international ... its UK equivalent. In addition to offering customers the flexibility to ... needs and budgets, International Solutions enables customers to tailor their benefits ... , ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AVIVA's Private Health Insurance Products Solutions Go International 2
... **SAVE THE DATE** April 14-16, 2009 in ... www.worldhealthcarecongress.com WOBURN, Mass., Feb. 19 At ... top leaders and innovators who are driving the $2.4 ... Safeway, Carlson Companies and Kelly Services who are responsible ...
... Founded Medical IT Company Launches into EXACENT,s Virtualized Environment , ... ... leading enterprise grade - on demand virtual data center , ... customer. , , ,HybridChart, a Scottsdale based company, has developed innovative ...
... blood pressure medicines helps maintain proper organ function, study ... combination of two blood pressure-lowering drugs reduced the risk ... with type 2 diabetes, according to researchers who analyzed ... patients. , The patients were randomly selected to receive ...
... difference, study finds, , , THURSDAY, Feb. 19 (HealthDay News) -- ... so-called Alzheimer,s gene might very well have the memory of ... This memory decline was not detected in people of middle ... the gene, known as ApoE4, according to the study. ...
... always been a vital issue for Americans but the current ... wellness. The two are far more closely related than people ... found that debt stress is a major contributor to health ... health problems, 20% more likely to have back pain and ...
... P&M Corporate Finance LLC, a,middle market investment banking ... Spine Technology Summit from RRY Publications. As part of ... will,continue to be actively involved in future Spine Technology ... 27, 2009 in London. , ...
Other Medicine News:Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 2Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 3Health News:EXACENT To Provide IT VIirtualization To HybridChart 2Health News:EXACENT To Provide IT VIirtualization To HybridChart 3Health News:Two-Drug Combo May Lower Diabetics' Kidney Risk 2Health News:If Parents Had Alzheimer's, Aging May Come Early 2Health News:If Parents Had Alzheimer's, Aging May Come Early 3Health News:Recession Spawns Vital New Industry - Financial Wellness 2Health News:Recession Spawns Vital New Industry - Financial Wellness 3Health News:P&M Corporate Finance Announces Acquisition of Spine Technology Summit, Partners with Robin Young to Present 2009 Conference in Canary Wharf London 2
Suture retriever forceps...
Knife rasp for shoulder arthroscopy....
Knot pusher/suture retriever...
Loop handle knot pusher...
Medicine Products: